Tumour suppressant protein, p53, is a transcription factor specific to the sequence activated by cell stress. The p53 media the cessation of the cell cycle or the apoptosis in response to damage to the DNA or the deprivation of the body's...
Tumour suppressant protein, p53, is a transcription factor specific to the sequence activated by cell stress. P53 media discontinuation of cell cycle or l'apoptosis in response to damage to the DNA or food deprivation for pyrimidine nucleotides. P53 is regulated in response to stress signals and stimulated to activate transcription of specific genes, resulting in the expression of p21waf1 and other proteins involved in stopping G1 or G2/M. The p53 structure includes a N-terminal end transactivation domain, a central DNA binding domain, a domain of oligomerization and a regulatory domain of the C-terminal end. There are various p53 phosphorylation sites, including Ser15 phosphorylation, which is important for p53 activation and stabilization. P53 was characterized as a factor in blocking the proliferative action of damaged cells and acting as an anticancer agent. The phosphorylation of Ser392 in p53 has been shown to be related to the formation of human tumours. P53 was also related to the effects of aging and oxidative stress and that an increase of p53 was related to the deficits of PLT in learning and memory. P53 is found in very small amounts in normal cells, however, in a variety of transformed cell lines, it is expressed in high quantities and appears to contribute to transformation and malignancy. P53 mutants that occur frequently in a number of human cancers do not bind the consensus sequence binding site of the DNA and cause loss of tumour suppressive activity.
Sensitivity
Sensitivity of the dosage: 0.32 ng/ml.
Measurement range
Dose range: 0.328 to 80 ng/ml.
Duration of dosing
Total duration of dosing: 4 h 45 min.
Reproducibility
Coefficient of intradose variation < 10%, interdose < 12%.
Technical specifications
| General |
| Brand | Invitrogen |
| Supplier ref. (Fisher Scientific) | 17798213 |
| Specifications |
| Accession number | P10361 |
| Dose range | 0.328 to 80 ng/ml |
| Sensitivity of the dosage | 0.32 ng/ml |
| Conjugate | Biotin |
| Product type | ELISA |
| Type of sample | Plasma, Serum, Surnatant |
| For use with (equipment) | Colorimetric microplate reader |
| Genetic identification (Enter) | 24842 |
| Gene symbol(s) | Tp53 |
| Coefficient of inter-dose variation | < 12% |
| Coefficient of intra-dose variation | < 10% |
| Contents of kits | 96-well pre-coated sheetings, etc., at the same time as the pre-casting plate, at the same time as the pre-casting plate. |
| Marker or dye | HRP |
| Quantity | 10 x 96 tests |
| Regulatory status | RUO |
| Target | p53 |
| Test time | 1 h 20 min |
| Physical characteristics |
| Volume of sample | Supernatant, 50 μl-Plasma, 50 μl-Sera, 50 μl |
| Storage and shipping |
| Storage conditions | 2°C to 8°C |
| Total duration of dosing | 4 h 45 min |
Origin and customs
| Manufacturer ref. | ERA47RBX10 |
|---|
| Country of origin | United States |
|---|
| HS customs code | 3002 12 00 00 |
|---|
A question or a specific configuration?
Contact us for a quote.